CG
PDSB icon

Cutler Group’s PDS Biotechnology PDSB Stock Holding History

Cutler Group’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$1K – 4483
2022
Q4 		$1K Buy
+300
New +$2.12K ﹤0.01% 4110
2021
Q4 		– Sell
-800
Closed -$4K – 5876
2021
Q3 		$4K Sell
800
-300
-27% -$3.74K ﹤0.01% 4651
2021
Q2 		$2K Buy
+1,100
New +$8.59K ﹤0.01% 5047

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's PDSB Position: Q3 2022 in Review

Cutler Group sold out of PDS Biotechnology (PDSB) in Q3 2022, closing a stake of 800 shares — an estimated $2K sold.

Cutler Group first reported a position in PDSB in Q2 2021 and held it in 5 quarters. The position peaked at $36K in Q2 2021. 47 funds tracked by Wall St. Rank hold PDSB as of Q3 2022.

  • Cutler Group reported no remaining PDS Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 800 PDS Biotechnology shares in Q3 2022, an estimated $2K.
  • Cutler Group first reported a position in PDS Biotechnology in Q2 2021 and held it in 5 quarters.
  • Cutler Group's PDS Biotechnology position peaked at $36K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.